ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "myositis and polymyositis/dermatomyositis (PM/DM)"

  • Abstract Number: 375 • 2018 ACR/ARHP Annual Meeting

    Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”

    Johannes Knitza, Hannah Schenker, Georg Schett and Jörg Distler, Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Antisynthetase Syndrome is a rare and severe autoimmune inflammatory disease that is associated with autoimmunity against aminoacyl-tRNA synthetase and clinical signs of arthritis, myositis…
  • Abstract Number: 397 • 2018 ACR/ARHP Annual Meeting

    Myositis-Specific Autoantibodies and Their Clinical Associations

    Victor Tak Lung Wong1, Ho So1, Ricky Wai Ki Ip2, Virginia W Lao3, Steve H Pang3, Lai-Shan Tam4, Priscilla Wong5, Lydia Ho Pui Tam6, Tsz On Lam7, Mei Yan Law8, Isaac CW Yim9, Tin Lok LAI10, Patrick Man Leung Lee11 and Ronald Man Lung Yip12, 1Kwong Wah Hospital, Kowloon, Hong Kong, 2Queen Mary Hospital, Hong Kong, Hong Kong, 3Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, 5Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 6Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 7Prince of Wales Hospital, New Territories, Hong Kong, 8Alice Ho Miu Ling Nethersole Hospital, New Territories, Hong Kong, 9Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, 10Medicine, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong, 11Yan Chai Hospital, Kowloon, Hong Kong, 12Tung Wah Group of Hospitals, Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Myositis-specific autoantibodies (MSAs) have been shown to predict clinical features and have prognostic implications in patients with idiopathic inflammatory myopathies (IIMs), with anti-melanoma differentiation-associated…
  • Abstract Number: 2133 • 2017 ACR/ARHP Annual Meeting

    Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study

    Akira Nishino, Yasuhiro Katsumata, Hidenaga Kawasumi, Yasushi Kawaguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Patients with polymyositis (PM) and dermatomyositis (DM) often experience relapse–remitting courses and recurrent myositis. However, only a few studies focused on this issue, and…
  • Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting

    Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –

    Yuki Ishikawa1,2, Ran Nakashima1, Takaki Nojima3,4, Takuya Isayama5, Nobuo Kuramoto1, Kosaku Murakami1, Hajime Yoshifuji1, Koichiro Ohmura1 and Tsuneyo Mimori1, 1Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 3Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Nojima Internal Medicine Clinic, Hiroshima, Japan, 5Medical & Biological Laboratories CO.,LTD., Nagoya, Japan

    Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…
  • Abstract Number: 298 • 2015 ACR/ARHP Annual Meeting

    Investigating the Pathogenic Role of ER Stress Pathway Activation in the Idiopathic Inflammatory Myopathies (IIM): Skeletal Muscle Cells As a Source of Cytokines (Myokines)

    Adam P. Lightfoot1, Katarzyna Goljanek-Whysall2, Kate E. Earl2, Caroline V. Cotton2, Anne McArdle1 and Robert G. Cooper3, 1Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3Rheumatic Diseaes Center, Salford Royal Foundation Trust, University of Manchester, Salford, United Kingdom

    Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a collection of autoimmune disorders, characterised by the development of debilitating symmetrical skeletal muscle weakness. IIM Patients also…
  • Abstract Number: 306 • 2015 ACR/ARHP Annual Meeting

    Investigating the Pathogenic Role of ER Stress Pathways in the Idiopathic Inflammatory Myopathies (IIM): Interrogating the Role of Micro-RNA 133a As an Important Regulator of ER Stress Activation

    Adam P. Lightfoot1, Katarzyna Goljanek-Whysall2, Anne McArdle1 and Robert G. Cooper3,4, 1Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3Rheumatic Diseaes Center, Salford Royal Foundation Trust, University of Manchester, Salford, United Kingdom, 4MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) is a heterogeneous group of acquired autoimmune disorders, characterised by symmetrical muscle weakness. Whilst immune cells clearly play a…
  • Abstract Number: 910 • 2014 ACR/ARHP Annual Meeting

    The Selective Sphingosine-1- Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial

    Katalin Danko1, Jiri Vencovsky2, Ingrid E. Lundberg3, Anthony A Amato4, Chester V. Oddis5, Maria Molnar6, Antonette Mallari Moher7, Laurence Colin8, Florian Muellershausen9, David Lee10 and Peter Gergely9, 1Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, 2Institute of Rheumatology, Charles University, Prague, Czech Republic, 3Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, 7Translational Medicine, Novartis Institutes for Biomedical Research (former emplyee), Basel, Switzerland, 8Novartis Pharma, Basel, Switzerland, 9Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, Basel, Switzerland

    Background/Purpose Polymyositis and dermatomyositis (PM/DM) comprise a heterogeneous group of chronic inflammatory muscle diseases where infiltration of lymphocytes in the skeletal muscle plays a key…
  • Abstract Number: 222 • 2012 ACR/ARHP Annual Meeting

    Lung Nodules in Patients with Idiopathic Inflammatory Myopathies

    Laura C. Cappelli1, Andrew L. Mammen2, Sonye K. Danoff3, Grant H. Louie4, Thomas E. Lloyd5 and Lisa Christopher-Stine6, 1Ste 4500, Johns Hopkins University, Baltimore, MD, 2NIAMS, NIH, Bethesda, MD, 3Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5Neurology, Johns Hopkins, Baltimore, MD, 6Medicine and Neurology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: The idiopathic inflammatory myopathies are associated with an increased incidence of malignancy, and interstitial lung disease (ILD) has been reported in as many as…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology